We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Spot Urine Sample Evaluated for Renal Potassium Loss

By LabMedica International staff writers
Posted on 02 Dec 2020
Hypokalemia is characterized by low serum potassium concentrations. Severe hypokalemia can be life threatening, and immediate potassium replacement is often required to prevent sudden cardiac arrest.

Initial identification of hypokalemia etiology is based on an estimate of urine potassium excretion during a 24-hr urine collection in the absence of potassium supplementation, but the utility of this approach in the emergency department is limited.

Endocrinologists at The Affiliated Hospital of Southwest Medical University (Luzhou, China) divided patients with hypokalemia were into two groups: 67 patients with hypokalemia caused by renal potassium loss and 63 patients with hypokalemia caused by extrarenal potassium loss. Arterial blood gases were measured with an ABL800 blood gas analyzer (Radiometer, Copenhagen, Denmark).

Urine potassium concentration (UK), urine creatinine concentration (UCr), urine potassium-creatinine ratio (UK/UCr), fractional excretion of potassium (FEK), transtubular potassium concentration gradient (TTKG), and 24-h urine potassium excretion (24 hUK-calculated) were derived from spot urine samples collected on admission, and were determined using automated methods on a 7170A automatic biochemistry analyzer (Hitachi Healthcare, Tokyo, Japan).

The scientists reported that patients with hypokalemia caused by renal potassium loss had significantly higher UK, UK/UCr, FEK, TTKG and 24 hUK-calculated compared to patients with hypokalemia caused by extrarenal potassium loss. FEK predicted renal potassium loss in hypokalemia with high accuracy at a cut-off of 9.29% (sensitivity, 80.6%; specificity, 85.7%). Patients with primary aldosteronism had significantly higher UK and TTKG compared to patients without primary aldosteronism. There were no significant differences in UK/UCr, FEK or 24 hUK-calculated between patients with primary aldosteronism and not primary aldosteronism. On the spot urine test, FEK showed the highest correlation with 24 hUK-actual during low or high dose potassium chloride infusion.

The authors concluded that prompt treatment with potassium chloride is required for patients with hypokalemia; 24 hUK-actual is not a suitable marker for predicting renal potassium loss in medical practice. Findings from this study suggest that a spot urine sample collected before potassium chloride therapy has utility for differentiating between renal and extrarenal potassium loss in hypokalemia. FEK from a spot urine sample represents a convenient and reliable parameter to predict renal potassium loss in patients with hypokalemia. The study will be published in the December, 2020 issue of the journal Clinica Chimica Acta.

Related Links:
The Affiliated Hospital of Southwest Medical University
Radiometer
Hitachi Healthcare



Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
High Performance Centrifuge
CO336/336R
New
Vaginitis Test
Allplex Vaginitis Screening Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.